- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Uncontrolled severe asthma; Severe chronic spontaneous urticaria; Uncontrolled severe allergic asthma.
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 885KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 150KB)
Omalizumab – November 2021
Omalizumab : Injection 75 mg in 0.5 mL single dose pre-filled syringe, Injection 150 mg in 1 mL single dose pre-filled syringe; Xolair®
Last updated
18 March 2022